La vendita allo scoperto per Minerva Neurosciences dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Minerva Neurosciences. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Minerva Neurosciences (NASDAQ:NERV) Azioni, Report sulle vendite allo scoperto

MINERVA NEUROSCIENCES INC

Minerva Neurosciences

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences Inc

NERVGEN PHARMA CORP by NervGen Pharma Corp.

NervGen Pharma Corp

NerveNetwork

Nervos Network

Earnings

Earnings Beats

News

NERV

Minerva Neurosciences Q1 EPS $(0.50) Beats $(1.07) Estimate

<h3>Gainers</h3>
<ul>
<li>Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) stock rose 21.4% to $4.7 during Monday's after-market session. The company's market cap stands at $35.8 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 15.01% to $0.25. The market value of their outstanding shares is at $11.0 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares rose 9.52% to $0.69. The company's market cap stands at $16.4 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares moved upwards by 8.26% to $4.06. The market value of their outstanding shares is at $2.6 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) shares moved upwards by 7.83% to $0.34. The company's market cap stands at $19.8 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock increased by 7.61% to $8.34. The market value of their outstanding shares is at $6.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares decreased by 29.9% to $0.75 during Monday's after-market session. The market value of their outstanding shares is at $7.0 million. </li>
<li>Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) stock fell 16.07% to $141.77. The company's market cap stands at $4.0 billion. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock declined by 13.67% to $0.56. The company's market cap stands at $98.4 million. </li>
<li>Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) stock declined by 12.11% to $1.38. The market value of their outstanding shares is at $9.6 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 10.42% to $0.21. The company's market cap stands at $1.3 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock decreased by 9.31% to $1.17. The market value of their outstanding shares is at $12.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BCAB

BSGM

CRIS

GOVX

HCTI

KRYS

MCRB

NAOV

POCI

VERO

YCBD

12 Health Care Stocks Moving In Monday's After-Market Session

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) with a Neutral and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Neutral on Minerva Neurosciences, Maintains $5 Price Target

Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(1.05) by 46.67 percent. This is a 52.94 percent increase over losses of $(1.19) per share from the same period last year.

Minerva Neurosciences Q4 2024 GAAP EPS $(0.56) Beats $(1.05) Estimate, Cash, Cash Equivalents And Restricted Cash At December 31, 2024, Were Approximately $21.5M

Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) reported quarterly earnings of $2.97 per share which may not be comparable to analyst consensus estimate of $(1.01). This is a 388.35 percent increase over losses of $(1.03) per share from the same period last year.

Minerva Neurosciences Q3 2024 GAAP EPS $2.97 May Not Be Comparable To $(1.01) Estimate

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) with a Neutral and lowers the price target from $7 to $5.

HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Lowers Price Target to $5

Minerva Neurosciences Q2 2024 GAAP EPS $(1.09) Misses $(0.73) Estimate, Cash, Cash Equivalents And Restricted Cash At June 30, 2024 Were Approximately $31M

Roche (OTC: <a class="ticker" href="https://www.benzinga.com/stock/rhhby#OTC">RHHBY</a>) announced that the European Commission has granted marketing authorization to the subcutaneous&nbsp;formulation of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) drug Ocrevus (ocrelizumab).
The approval is based on pivotal data from the late-stage OCARINA II trial, which showed non-inferior levels of the drug in the blood when administered subcutaneously, and a safety and efficacy profile comparable to the intravenous (IV) formulation in patients with RMS and PPMS.
The SC formulation of Ocrevus was developed to provide an alternative twice-a-year treatment option to patients and healthcare professionals, in addition to IV.
Ocrevus SC combines Ocrevus with Halozyme Therapeutics&#39; ENHANZE drug delivery technology.
Roche also announced that the European Medicines Agency (&quot;EMA&quot;) has validated and initiated review of the marketing authorization application&nbsp;for Elevidys (delandistrogene moxeparvovec).Elevidys, a gene therapy for the treatment of ambulatory patients aged 3-7 years with Duchenne muscular dystrophy, is already approved in the United States and some other countries. It is a one-time treatment administered through a single IV dose.
The MAA is based on results from the phase III EMBARK study, a global, randomized, double-blind, placebo-controlled study in DMD patients aged 4 through 7 years. Although the EMBARK study did not meet the primary endpoint, the totality of evidence from the trial confirmed that Elevidys is the first gene therapy to provide clinically meaningful benefits for patients by modifying the disease course, with a manageable safety profile.
Elevidys-treated patients reported clinically meaningful and statistically significant benefits in both key secondary functional endpoints &mdash; time to rise from the floor and a ten-minute walk/run test.
In addition, a clinically meaningful and statistically significant improvement was observed for the pre-specified secondary endpoint &mdash; stride velocity 95th centile.
The MAA is also supported by data from another study in DMD patients, ENDEAVOR, an open-label study that is enrolling ambulatory and non-ambulatory patients of various ages, along with a phase I/II study which provides long-term efficacy, durability, safety and biological data to support the benefit-risk assessment.
Per Roche, a potential approval will make Elevidys the first and only gene therapy to address the underlying cause of DMD, available in Europe.
Two other studies are also currently ongoing to expand the drug&#39;s label ENVOL, a phase II study in boys with DMD under the age of 4 and ENVISION, a phase III study in older ambulatory and non-ambulatory patients with DMD.
Roche has a collaboration agreement with Sarepta Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srpt#NASDAQ">SRPT</a>) for Elevidys, whereby it is responsible to commercialize Elevidys outside the United States.
Last week, Sarepta announced that the FDA has converted the accelerated approval granted to Elevidys to a traditional approval and expanded the label to include ambulatory individuals with a confirmed mutation in the DMD gene who are aged four and older. In addition, the FDA also granted accelerated approval to Elevidys for non-ambulatory Duchenne patients.
Roche&#39;s shares have lost 1.4% year to date against the industry&#39;s growth of 22.1%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6e/69510.jpg?v=187863424" /> 
Image Source: Zacks Investment Research
Approval of new drugs and label expansion of the existing ones should bode well for Roche in this scenario.
Drugs like Vabysmo, Ocrevus, Hemlibra and Polivy fuel Roche&#39;s top line as the company looks to fill up the dent in revenues caused by a decline in COVID-19-related sales. Competition from biosimilars for established drugs like Avastin, MabThera/Rituxan and Herceptin continues to hurt sales.
<h3>Zacks Rank &amp; Other Stocks to Consider</h3>
Roche currently carries a Zacks Rank #2 (Buy).
A couple of other top-ranked stocks in the healthcare sector are ALX Oncology Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alxo#NASDAQ">ALXO</a>) and Minerva Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nerv#NASDAQ">NERV</a>), each carrying a Zacks Rank #2 at present.
In the past 60 days, the Zacks Consensus Estimate for ALX Oncology&#39;s 2024 loss per share has narrowed from $3.33 to $2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to $2.73.
ALX Oncology beat on earnings in two of the trailing four quarters and missed the mark in the other two, delivering an average negative surprise of 8.83%.
In the past 60 days, estimates for Minerva Neurosciences&#39; 2024 loss per share have narrowed from $3.57 to $1.89. The loss per share estimate for 2025 has narrowed from $4.54 to $3.60 during the same time frame.
NERV&#39;s earnings beat estimates in one of the trailing four quarters and missed the same in the other three, the average negative surprise being 54.43%.
<a href="https://www.zacks.com/stock/news/2293133/roche-s-rhhby-ocrevus-subcutaneous-gets-european-commission-nod?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2293133">To read this article on Zacks.com click here.</a>

Penny Stocks

Health Care

Small Cap

Markets

Trading Ideas

General

ALXO

RHHBY

SRPT

Roche's Ocrevus Subcutaneous Gets European Commission Nod

Ultragenyx Pharmaceutical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rare#NASDAQ">RARE</a>), along with partner Mereo BioPharma (MREO), announced new positive 14-month data from the phase II portion of the phase II/III Orbit study evaluating setrusumab (UX143) in patients with osteogenesis imperfecta.
The data showed that the large reduction in fracture rates previously reported in patients treated for a minimum of six months was sustained in patients treated for at least 14 months.
OI is a group of genetic disorders that impact bone metabolism. It is characterized by increased bone fragility and a high risk of fractures. Currently, there are no approved treatments for this debilitating condition, representing a highly unmet medical need.
As of the data cut-off date of May 24, 2024, the new data showed that treatment with setrusumab resulted in&nbsp;a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00.
Treatment with setrusumab also resulted in clinically meaningful continued improvement in lumbar spine bone mineral density (BMD) with a mean increase from baseline of 22% at the 12-month timepoint.
Previously, the company reported that treatment with setrusumab for at least six months reduced the annualized fracture rate by 67% in patients with OI.
Per the company, the new data underlines the potential of setrusumab in reducing the incidence of fractures and improving BMD in patients with OI.
No treatment-related serious adverse effects were seen as of the data cut-off date.
Shares of Ultragenyx have plunged 13.4% so far this year compared with the industry&#39;s decline of 5.5%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/66/68681.jpg?v=1385493297" /> 
Image Source: Zacks Investment Research
Setrusumab, a fully human monoclonal antibody, is an inhibitor of the sclerostin protein, which is responsible for hampering the maturation and activity of bone-forming cells.
We would like to remind investors that Ultragenyx entered into a licensing and collaboration agreement with Mereo in December 2020 to co-develop setrusumab. Per the terms of the agreement, Ultragenyx leads the global development of setrusumab in both pediatric and adult patients with OI.
As part of this deal, Mereo received an upfront payment of $50 million from RARE, while the latter is eligible for certain regulatory and sales-based milestone payments.
Meanwhile, enrollment in the pivotal phase III portion of the phase II/III Orbit study has been completed. Patients in this portion of the study will be divided into two cohorts in a ratio of 2:1, receiving either a 20 mg/kg dose of setrusumab or a placebo. The primary efficacy endpoint of the study is the annualized clinical fracture rate. Per Ultragenyx, all patients will transition to an extension period and receive open-label setrusumab after completing the primary analysis in the phase III portion of the study.
Apart from the Orbit study, the phase III Cosmic study is also evaluating the effect of setrusumab compared with intravenous bisphosphonate therapy on the annualized total fracture rate in patients aged 2 to &lt;7 years. Enrollment in this study has also been completed.
<h3>Zacks Rank &amp; Stocks to Consider</h3>
Ultragenyx currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are Acrivon Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acrv#NASDAQ">ACRV</a>), Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) and Minerva Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nerv#NASDAQ">NERV</a>), each carrying a Zacks Rank #2 (Buy) at present.
In the past 60 days, estimates for Acrivon Therapeutics&#39; 2024 loss per share have narrowed from $3.42 to $2.47. Loss per share estimates for 2025 have narrowed from $3.36 to $2.55. Year to date, shares of ACRV have surged 50.4%.
ACRV&#39;s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining one occasion, the average surprise being 3.56%.
In the past 60 days, estimates for Marinus Pharmaceuticals&#39; 2024 loss per share have narrowed from $2.43 to $1.87, while loss per share estimates for 2025 have narrowed from $1.97 to 90 cents. Year to date, shares of MRNS have plunged 85.7%.
MRNS&#39;s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same once, the average surprise being 3.27%.
In the past 60 days, estimates for Minerva Neurosciences&#39; 2024 loss per share have narrowed from $3.57 to $1.89. Loss per share estimates for 2025 have narrowed from $4.54 to $3.60. Year to date, shares of NERV have declined 47.1%.
NERV&#39;s earnings beat estimates in one of the trailing four quarters while missing the same on the remaining three occasions, the average negative surprise being 54.43%.
<a href="https://www.zacks.com/stock/news/2287344/ultragenyx-rare-posts-new-data-from-bone-disease-study?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2287344">To read this article on Zacks.com click here.</a>

Biotech

ACRV

MRNS

RARE

Ultragenyx Posts New Data From Bone Disease Study

Candel Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cadl#NASDAQ">CADL</a>) announced overall survival data from a phase II study evaluating its lead investigational adenovirus immunotherapy candidate, CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) in patients with stage III/IV non-small cell lung cancer (NSCLC) who are non-responsive to immune checkpoint inhibitor therapy.
Data from the study showed that treatment with two administrations of CAN-2409 plus valacyclovir led to a median overall survival of 20.6 months in NSCLC patients whose disease had progressed despite receiving prior anti-PD-1 treatment.
The data will be presented at the annual meeting of the American Society of Clinical Oncology, which is scheduled to be held from May 31 to Jun 4, 2024.
Per the press release, the above mentioned data was in context to earlier published data, which demonstrated a median overall survival of 11.6 months observed with standard-of-care docetaxel-based chemotherapy in a similar patient population.
Importantly, treatment with CAN-2409 exhibited a favorable safety and tolerability profile in NSCLC patients as of the data cut-off date.
Despite the upbeat data, shares of Candel were down in pre-market trading on May 23. The stock has skyrocketed 627.2% year to date against the industry&#39;s decline of 4.3%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a1/67450.jpg?v=309181717" /> 
Image Source: Zacks Investment Research
Apart from NSCLC, CAN-2409 is also being developed for several cancer indications, including pancreatic ductal adenocarcinoma (PDAC) and prostate cancer.
Last month, CADL announced positive interim data from the phase II study evaluating CAN-2409 plus valacyclovir, together with SoC chemoradiation, followed by resection for borderline resectable PDAC.
The updated interim data from the ongoing phase II study showed that experimental treatment with CAN-2409 led to notable improvements in estimated median overall survival of 28.8 months compared with only 12.5 months in the control group in borderline resectable PDAC.
The FDA granted Fast Track designation to CAN-2409 for the treatment of pancreatic cancer and NSCLC.
In the absence of a marketed product, the successful development of its pipeline candidates remains the key focus for this clinical-stage biopharmaceutical company.
<h3>Zacks Rank &amp; Stocks to Consider</h3>
Candel currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>), Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) and Minerva Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nerv#NASDAQ">NERV</a>), each carrying a Zacks Rank #2 (Buy) at present.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have improved from $1.61 to $2.06. Earnings per share estimates for 2025 have improved from $3.69 to $4.33. Year to date, shares of KRYS have surged 31.9%.
KRYS&#39;s earnings beat estimates in two of the trailing four quarters and missed the same on the remaining two occasions, the average negative surprise being 21.46%.
In the past 60 days, estimates for Marinus Pharmaceuticals&#39; 2024 loss per share have narrowed from $2.44 to $1.87, while loss per share estimates for 2025 have narrowed from $1.97 to 90 cents. Year to date, shares of MRNS have plunged 88%.
MRNS&#39;s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same once, the average surprise being 3.27%.
In the past 60 days, estimates for Minerva Neurosciences&#39; 2024 loss per share have narrowed from $3.57 to $1.89. Loss per share estimates for 2025 have narrowed from $4.54 to $3.60. Year to date, shares of NERV have declined 59.1%.
NERV&#39;s earnings beat estimates in one of the trailing four quarters while missing the same in the remaining three occasions, the average negative surprise being 54.43%.
<a href="https://www.zacks.com/stock/news/2278806/candel-cadl-reports-upbeat-data-from-lung-cancer-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-2278806">To read this article on Zacks.com click here.</a>

CADL

Candel Reports Upbeat Data From Lung Cancer Study

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) with a Neutral and lowers the price target from $11 to $7.

HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Lowers Price Target to $7

Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $(1.20) by 5.83 percent. This is a 13.74 percent increase over losses of $(1.31) per share from the same period last year.

Minerva Neurosciences Q1 2024 GAAP EPS $(1.13) Beats $(1.20) Estimate; Cash, Cash Equivalents And Restricted Cash Of $34.9M

Minerva Neurosciences On April 10, Got Notice From Nasdaq That Company Was Not In Compliance With Nasdaq's Listing Rule

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday.
The Dow traded down 0.35% to 38,932.26 while the NASDAQ rose 0.28% to 16,021.41. The S&amp;P 500 also rose, gaining, 0.04% to 5,071.40.
Check This Out: <a href="https://www.benzinga.com/news/24/02/37331804/wall-streets-most-accurate-analysts-views-on-3-risk-off-stocks-with-over-5-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Risk Off Stocks With Over 5% Dividend Yields </a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Utilities shares rose by 1.2% on Tuesday.
In trading on Tuesday, energy shares fell by 0.4%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
The J.M. Smucker Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sjm#NYSE">SJM</a>) posted better-than-expected earnings for its fourth quarter on Tuesday.
The company reported third-quarter adjusted earnings per share of $2.48, beating the analyst consensus of $2.27. J.M. Smucker registered quarterly revenues of $2.229 billion, marginally beating the consensus estimate of $2.220 billion.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) shares shot up 191% to $44.00 after the company announced updated clinical data for both of its clinical programs.
Shares of Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>) got a boost, surging 32% to $13.50 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.
Viking Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vktx#NASDAQ">VKTX</a>) shares were also up, gaining 94% to $74.79 after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Minerva Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nerv#NASDAQ">NERV</a>) shares dropped 57% to $2.95 after the company announced it received a Complete Response Letter from the FDA for the New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
Shares of Thoughtworks Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/twks#NASDAQ">TWKS</a>) were down 31% to $3.1785 after the company reported worse-than-expected fourth-quarter financial results and issued weak guidance.
NRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrxp#NASDAQ">NRXP</a>) was down, falling 33% to $0.2851 after the company announced pricing of $1.5 million underwritten public offering of common stock at a price of $0.30/share together with investor commitment for additional $1 million.
Also Check This Out:<a href="https://www.benzinga.com/news/24/02/37334066/top-3-energy-stocks-that-could-sink-your-portfolio-in-q1"> Top 3 Energy Stocks That Could Sink Your Portfolio In Q1 </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 1.6% to $78.81 while gold traded up 0.1% at $2,041.60.
Silver traded fell 0.3% to $22.46 on Tuesday while copper rose 0.4% to $3.85.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares closed mixed today. The eurozone&rsquo;s STOXX 600 fell 0.18%, London&rsquo;s FTSE 100 fell 0.02% while Spain&rsquo;s IBEX 35 Index fell 0.24% The German DAX gained 0.76% French CAC 40 rose 0.23% while Italy&rsquo;s FTSE MIB Index rose 0.46%.
Bank lending to households in the Eurozone rose by 0.3% year-over-year to EUR 6.870 trillion for January. The consumer confidence indicator in France declined to 89 in February versus around two-year high level of 91 in the prior month. The GfK Consumer Climate Indicator for Germany climbed to a reading of -29.0 heading into March compared to February&#39;s level of 29.6.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 0.01%, Hong Kong&rsquo;s Hang Seng Index climbing 0.94%, China&rsquo;s Shanghai Composite Index surging 1.29% and India&rsquo;s S&amp;P BSE Sensex gaining 0.4%.
Hong Kong recorded a trade surplus of $3.6 billion in January compared to a year-ago deficit of $25.4 billion. The annual inflation rate in Japan slowed to 2.2% in January compared to 2.6% in the earlier month.
&nbsp;
<h3>Economics</h3>
&nbsp;
U.S. durable goods orders fell by 6.1% month-over-month in January compared to a 0.3% decline in December.
The FHFA house price index rose 0.1% in December following a 0.4% increase in November.
The S&amp;P CoreLogic Case-Shiller 20-city home price index climbed by 6.1% year-over-year in December.
The Dallas Fed general business activity index for Texas&rsquo; service sector rose to -3.9 in February from -9.3 in the previous month
Now Read This: <a href="https://www.benzinga.com/news/24/02/37333478/roku-crocs-and-2-other-stocks-insiders-are-selling"> Roku, Crocs And 2 Other Stocks Insiders Are Selling </a>
&nbsp;

Eurozone

Commodities

Global

Intraday Update

Hims & Hers Health, Inc. Class A Common Stock

HIMS

JANX

NRXP

TWKS

VKTX

Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings

Shares of Helix Energy Solutions Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlx#NYSE">HLX</a>) fell sharply during Tuesday&rsquo;s session following weak earnings.
Helix Energy posted adjusted earnings of 6 cents per share, missing market estimates of 10 cents per share. The company&rsquo;s quarterly sales came in at $335.16 million versus expectations of $315.60 million.
Helix Energy Solutions shares dipped 11% to $9.13 on Tuesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) shares jumped 145% to $37.00 after the company announced updated clinical data for both of its clinical programs.</li>
<li>Presto Automation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prst#NASDAQ">PRST</a>) surged 72% to $0.5657.</li>
<li>Viking Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vktx#NASDAQ">VKTX</a>) shares jumped 71.2% to $65.88 after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints.</li>
<li>CXApp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cxai#NASDAQ">CXAI</a>) gained 67% to $2.58.</li>
<li>WeTrade Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wetg#NASDAQ">WETG</a>) gained 50% to $3.36.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>) climbed 33.6% to $13.70 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>Biora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bior#NASDAQ">BIOR</a>) surged 32.2% to $1.39.</li>
<li>AdaptHealth Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ahco#NASDAQ">AHCO</a>) jumped 29.6% to $9.89 following fourth-quarter results.</li>
<li>Codexis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdxs#NASDAQ">CDXS</a>) rose 29% to $4.1283. Codexis entered into exclusive licensing agreement with Roche for double-stranded DNA Ligase.</li>
<li>Beam Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/beam#NASDAQ">BEAM</a>) gained 26.8% to $45.43 after the company reported fourth-quarter financial results.</li>
<li>BigBear.ai Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbai#NYSE">BBAI</a>) rose 26% to $3.14. Cantor Fitzgerald analyst Yi Fu Lee maintained BigBear.ai with an Overweight and maintained $3 price target.</li>
<li>5E Advanced Materials, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/feam#NASDAQ">FEAM</a>) gained 24.3% to $1.84.</li>
<li>Earlyworks Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elws#NASDAQ">ELWS</a>) gained 24.2% to $0.7321. Earlyworks was selected as a co-creation partner for MetaMe&reg; a meta-communication service utilizing cutting-edge technology from NTT DOCOMO, one of Japan&#39;s largest cell phone operators.</li>
<li>The Singing Machine Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mics#NASDAQ">MICS</a>) rose 24.1% to $0.9012.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smx#NASDAQ">SMX</a>) jumped 24% to $0.3299.</li>
<li>Ligand Pharmaceuticals Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgnd#NASDAQ">LGND</a>) gained 23% to $91.68 following upbeat quarterly earnings.</li>
<li>SoundHound AI, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soun#NASDAQ">SOUN</a>) jumped 22.3% to $7.03 after gaining more than 46% on Monday.</li>
<li>Pyxis Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pyxs#NASDAQ">PYXS</a>) gained 21.3% to $5.80. Pyxis Oncology announced a $50 million private placement.</li>
<li>PubMatic, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pubm#NASDAQ">PUBM</a>) shares climbed 20.8% to $20.01 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>bluebird bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blue#NASDAQ">BLUE</a>) jumped 20.5% to $1.76.</li>
<li>Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) gained 20.4% to $13.63.</li>
<li>Sterling Infrastructure, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/strl#NASDAQ">STRL</a>) jumped 19% to $107.00 after the company reported fourth-quarter financial results.</li>
<li>Denali Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dnli#NASDAQ">DNLI</a>) gained 17.6% to $19.87 following quarterly results.</li>
<li>National Vision Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eye#NASDAQ">EYE</a>) rose 17.6% to $23.48 following strong results.</li>
<li>Heidrick &amp; Struggles International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsii#NASDAQ">HSII</a>) gained 16.7% to $33.81 following strong results.</li>
<li>Ault Alliance, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ault#NASDAQ">AULT</a>) rose 15.8% to $0.4520. Ault Alliance announced record preliminary 2023 revenue of $153 million.</li>
<li>Portillo&#39;s Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptlo#NASDAQ">PTLO</a>) gained 15.6% to $15.90 following upbeat results.</li>
<li>Dorman Products, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dorm#NASDAQ">DORM</a>) climbed 11.5% to $92.67 following upbeat earnings.</li>
<li>Constellation Energy Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ceg#NASDAQ">CEG</a>) gained 9.7% to $146.27 following strong sales..</li>
<li>NovoCure Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvcr#NASDAQ">NVCR</a>) gained 9.5% to $16.31.</li>
<li>TransMedics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) gained 9.5% to $85.14 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Minerva Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nerv#NASDAQ">NERV</a>) shares dipped 56.9% to $2.93 after the company announced it received a Complete Response Letter from the FDA for the New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) fell 55.8% to $1.2180. The stock continues to experience marked volatility after the company on Monday said it encountered an unexpected delay in its planned reverse stock split.</li>
<li>NRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrxp#NASDAQ">NRXP</a>) fell 32.7% to $0.2878 after the company announced pricing of $1.5 million underwritten public offering of common stock at a price of $0.30/share together with investor commitment for additional $1 million.</li>
<li>Thoughtworks Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/twks#NASDAQ">TWKS</a>) fell 30.6% to $3.20 after the company reported worse-than-expected fourth-quarter financial results and issued weak guidance.</li>
<li>Alpine 4 Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alpp#NASDAQ">ALPP</a>) dipped 26% to $0.8799.</li>
<li>Stagwell Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stgw#NASDAQ">STGW</a>) fell 25.6% to $5.22 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Calidi Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cldi#NASDAQ">CLDI</a>) dipped 24.9% to $0.9084.</li>
<li>Clarivate Plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/clvt#NYSE">CLVT</a>) fell 23.3% to $6.85 after the company reported fourth-quarter financial results and issued guidance.</li>
<li>Edgio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egio#NASDAQ">EGIO</a>) fell 21.5% to $0.2450. Edgio announced effectiveness of reverse stock split.</li>
<li>Telesis Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tbio#NASDAQ">TBIO</a>) fell 21% to $0.5215 after tumbling 15% on Monday. Telesis Bio said it sees preliminary 2023 total consolidated revenue of $27.5 million.</li>
<li>Lotus Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lot#NASDAQ">LOT</a>) dipped 20.3% to $11.36.</li>
<li>Pineapple Energy Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pegy#NASDAQ">PEGY</a>) shares fell 19.6% to $0.0654. On Feb. 5. Pineapple Energy priced a $1 million registered direct offering of common stock.</li>
<li>The Aaron&#39;s Company, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aan#NYSE">AAN</a>) shares fell 16.7% to $8.71. Aaron&#39;s reported a loss for the fourth quarter, while sales missed estimates.</li>
<li>Perrigo Company plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/prgo#NYSE">PRGO</a>) fell 15.1% to $27.33 after the company reported fourth quarter financial results.</li>
<li>Intuitive Machines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lunr#NASDAQ">LUNR</a>) fell 10% to $5.64. Intuitive Machines said communications with moon lander Odysseus is expected to cease Tuesday morning, effectively ending mission 5 days after touchdown, Reuters reported.</li>
<li>Unity Software Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/u#NYSE">U</a>) fell 8.3% to $30.31 after the company reported mixed financial results for its fourth quarter. The company said it sees first-quarter strategic portfolio revenue in the range of $415 million to $420 million.</li>
<li>Primoris Services Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prim#NASDAQ">PRIM</a>) dipped 7.2% to $ 37.63 after the company reported mixed fourth quarter financial results.</li>
<li>LendingTree, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tree#NASDAQ">TREE</a>) fell 6.9% to $31.90 following weak sales.</li>
<li>CarGurus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/carg#NASDAQ">CARG</a>) shares fell 4.2% to $22.89 after the company reported fourth-quarter financial results.</li>
<li>Workday, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wday#NASDAQ">WDAY</a>) shares declined 2.9% to $298.42 after the company reported fourth-quarter financial results, reiterated guidance and announced its intent to acquire HiredScore.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/37328014/how-to-earn-500-a-month-from-ebay-stock-ahead-of-q4-earnings-report"> How To Earn $500 A Month From eBay Stock Ahead Of Q4 Earnings Report </a>

AHCO

ALPP

AULT

BBAI

BEAM

BIOR

BLUE

CARG

CDXS

CLDI

CLVT

CXAI

DNLI

DORM

EGIO

ELWS

FEAM

HSII

IFBD

LGND

LUNR

MICS

NVCR

PEGY

PRGO

PRIM

PRST

PTLO

PUBM

PYXS

SOUN

STGW

STRL

TBIO

TMDX

TREE

WDAY

WETG

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Minerva Neurosciences Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) shares are trading lower after the FDA issued a Complete Response Letter (CRL) to the company&#8217;s marketing application for roluperidone for the treatment of negative symptoms in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/g37332988/minerva-neurosciences-receives-complete-response-letter-from-fda-for-new-drug-application-for-rolu" rel="noreferrer noopener">patients with schizophrenia</a>.
In the CRL, the FDA cited the following clinical deficiencies:
<ul>
<li>Although one study (MIN-101C03) demonstrated statistical significance on the primary efficacy endpoint, it is insufficient on its own to establish substantial evidence of effectiveness.</li>
<li>&nbsp;The application submission lacks data on concomitant antipsychotic administration.</li>
<li>&nbsp;The NDA submission lacks the data needed to establish that the change in negative symptoms of schizophrenia with roluperidone treatment was clinically meaningful.</li>
<li>&nbsp;The submitted safety database included an inadequate number of subjects exposed to roluperidone at the proposed dose (64 mg) for at least 12 months.</li>
<li>&nbsp;To address these deficiencies, the FDA stated that Minerva must submit at least one additional positive, adequate, and well-controlled study to support the safety and effectiveness of roluperidone for treating negative symptoms.&nbsp;</li>
<li>&nbsp;Minerva must also provide additional data to demonstrate the safety and efficacy of roluperidone co-administered with antipsychotic medications, to support that observed effect on negative symptoms with roluperidone treatment corresponds to a clinically meaningful change, and to demonstrate the long-term safety of the proposed dose.</li>
</ul>
&#8220;We believe that roluperidone is a safe and effective therapy for negative symptoms of schizophrenia, and we will review FDA&#8217;s feedback and consider our potential paths forward, including continuing to work closely with the FDA and providing any additional information as needed,&#8221; said Dr. Remy Luthringer, Executive Chairman and CEO of Minerva.
In addition to the clinical deficiencies, the FDA also provided comments on, among other items, clinical pharmacology, product quality, biopharmaceutics, and nonclinical issues.
Cash, cash equivalents, and restricted cash at December 31, 2023, were&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/g37256959/minerva-neurosciences-reports-fourth-quarter-and-fiscal-year-2023-financial-results-and-business-u" rel="noreferrer noopener">approximately $41.0 million</a>.
Price Action:&nbsp;NERV shares are down 62.1% at $2.55 during the premarket session on the last check Tuesday.

Regulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More Data

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) with a Neutral and maintains $11 price target.

HC Wainwright & Co. Reiterates Neutral on Minerva Neurosciences, Maintains $11 Price Target

<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion. </li>
<li>Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares moved upwards by 91.96% to $73.87. The company's market cap stands at $7.4 billion. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares moved upwards by 41.81% to $2.34. The company's market cap stands at $156.7 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) shares rose 33.24% to $1.4. The market value of their outstanding shares is at $38.0 million. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) shares increased by 31.4% to $4.21. The company's market cap stands at $293.6 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares moved upwards by 31.02% to $13.43. The company's market cap stands at $2.8 billion. As per the news, the Q4 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) stock decreased by 57.1% to $2.92 during Tuesday's regular session. The market value of their outstanding shares is at $20.4 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) stock declined by 32.77% to $0.29. The company's market cap stands at $24.4 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares decreased by 24.93% to $0.91. The market value of their outstanding shares is at $32.2 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock fell 21.22% to $0.52. The company's market cap stands at $15.5 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) shares decreased by 15.21% to $0.49. The company's market cap stands at $2.5 million. </li>
<li>SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) stock decreased by 14.15% to $17.64. The market value of their outstanding shares is at $714.2 million. The company's, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTMX

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SIBN

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Tuesday.
The Dow traded down 0.39% to 38,915.65 while the NASDAQ rose 0.15% to 15,999.50. The S&amp;P 500 also fell, dropping, 0.03% to 5,067.80.
Check This Out: <a href="https://www.benzinga.com/news/24/02/37331804/wall-streets-most-accurate-analysts-views-on-3-risk-off-stocks-with-over-5-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Risk Off Stocks With Over 5% Dividend Yields </a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Utilities shares rose by 1.5% on Tuesday.
In trading on Tuesday, energy shares fell by 0.5%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Macy&rsquo;s Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/m#NYSE">M</a>) reported mixed quarterly results and announced plans to close 150 stores.
The company reported fourth-quarter adjusted EPS of $2.45, beating the analyst consensus of $1.96. Quarterly revenue of $8.12 billion missed the analyst consensus of $8.15 billion. Sales fell 1.7% year over year.
Macy&rsquo;s announced a new strategy, &ldquo;A Bold New Chapter,&rdquo; designed to return the company to enterprise growth. The company plans to focus on Macy&rsquo;s resources by closing approximately 150 underproductive locations through 2026.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) shares shot up 195% to $44.47 after the company announced updated clinical data for both of its clinical programs.
Shares of Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>) got a boost, surging 35% to $13.80 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.
Viking Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vktx#NASDAQ">VKTX</a>) shares were also up, gaining 100% to $76.92 after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Minerva Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nerv#NASDAQ">NERV</a>) shares dropped 58% to $2.88 after the company announced it received a Complete Response Letter from the FDA for the New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
Shares of Thoughtworks Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/twks#NASDAQ">TWKS</a>) were down 28% to $3.33 after the company reported worse-than-expected fourth-quarter financial results and issued weak guidance.
NRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrxp#NASDAQ">NRXP</a>) was down, falling 32% to $0.2901 after the company announced pricing of $1.5 million underwritten public offering of common stock at a price of $0.30/share together with investor commitment for additional $1 million.
Also Check This Out:<a href="https://www.benzinga.com/news/24/02/37334066/top-3-energy-stocks-that-could-sink-your-portfolio-in-q1"> Top 3 Energy Stocks That Could Sink Your Portfolio In Q1 </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 1% to $78.35 while gold traded up 0.2% at $2,042.60.
Silver traded fell 0.2% to $22.485 on Tuesday while copper rose 0.5% to $3.8520.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly higher today. The eurozone&rsquo;s STOXX 600 rose 0.24%, London&rsquo;s FTSE 100 rose 0.04% while Spain&rsquo;s IBEX 35 Index fell 0.22% The German DAX gained 0.78% French CAC 40 rose 0.29% while Italy&rsquo;s FTSE MIB Index rose 0.48%.
Bank lending to households in the Eurozone rose by 0.3% year-over-year to EUR 6.870 trillion for January. The consumer confidence indicator in France declined to 89 in February versus around two-year high level of 91 in the prior month. The GfK Consumer Climate Indicator for Germany climbed to a reading of -29.0 heading into March compared to February&#39;s level of 29.6.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 0.01%, Hong Kong&rsquo;s Hang Seng Index climbing 0.94%, China&rsquo;s Shanghai Composite Index surging 1.29% and India&rsquo;s S&amp;P BSE Sensex gaining 0.4%.
Hong Kong recorded a trade surplus of $3.6 billion in January compared to a year-ago deficit of $25.4 billion. The annual inflation rate in Japan slowed to 2.2% in January compared to 2.6% in the earlier month.
&nbsp;
<h3>Economics</h3>
&nbsp;
U.S. durable goods orders fell by 6.1% month-over-month in January compared to a 0.3% decline in December.
The FHFA house price index rose 0.1% in December following a 0.4% increase in November.
The S&amp;P CoreLogic Case-Shiller 20-city home price index climbed by 6.1% year-over-year in December.
The Dallas Fed general business activity index for Texas&rsquo; service sector rose to -3.9 in February from -9.3 in the previous month.
Now Read This: <a href="https://www.benzinga.com/news/24/02/37333478/roku-crocs-and-2-other-stocks-insiders-are-selling"> Roku, Crocs And 2 Other Stocks Insiders Are Selling </a>
&nbsp;

Crude Oil Gains 1%; Macy's Plans To Close 150 Stores

Press Releases

Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

Comments

Minerva Neurosciences

Vendite allo scoperto

Minerva Neurosciences (NASDAQ:NERV) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO